Selinexor 增强 NK 细胞对多发性骨髓瘤的活化
Selinexor potentiates NK cell activation against multiple myeloma.
这些数据揭示,selinexor 选择性破坏 MM 中的 2A:HLA-E 免疫检查点轴,并增强 NK 细胞活化以及对 MM 细胞的 ADCC。
肿瘤细胞治疗研究
ALL SOURCES
把在研试验和前沿论文合在一起看,按时间倒序排列。本页条数 = 前沿论文 + 临床试验两块之和(导航里的「临床试验」板块只收在招的那部分,不另计入)。
Selinexor potentiates NK cell activation against multiple myeloma.
这些数据揭示,selinexor 选择性破坏 MM 中的 2A:HLA-E 免疫检查点轴,并增强 NK 细胞活化以及对 MM 细胞的 ADCC。
High-dimensional spectral flow cytometry uncovers progressive T-cell exhaustion and myeloid cell reprogramming in a CLL mouse model.
Type-I interferon-activated NK cells control polycythemia vera in vivo.
Effector-cell-engaging bispecific antibodies for cancer therapeutics: Engineering precision immunity.
To express or not to express HLA-G: tissue undifferentiation is the answer in gastrointestinal tumors.
Transcriptomic Characterization of TCR-NK Cells Reveals Challenges Associated with CD3ζ Overexpression.
CD3ζ过表达在 TCR-NK 细胞工程中并非中性修饰。它与广泛的转录重塑和激活相关信号变化有关,这可能为先前观察到的非特异性活性增加提供分子背景。这些发现支持 TCR-NK 工程策略,即保留内源性 CD3ζ调控,同时仅引入功能性 TCR 表达所需的缺失 CD3δγε组分。
Profiling neoadjuvant therapy response in rectal cancer using meta-analysis of publicly available transcriptomic RNA-seq datasets.
Inflammatory bone marrow microenvironment impairs the therapeutic effect of daratumumab-lenalidomide in multiple myeloma.
Targeting Reactive Species Stress and Nutrient Sensing to Enhance NK-Cell Function: Mechanistic Strategies for Overcoming Pancreatic Cancer Progressio
MEMBER ACCOUNT
登录成功会直接打开下一页。